BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
我放心你带套猛
发表于 2 小时前
119
0
0
Domestic innovative pharmaceutical companies have once again exposed a deep-water bomb.
On October 25th, Yin Min, the Chief Commercial Officer of BeiGene Greater China, a leading domestic innovative pharmaceutical company, was exposed by the media to be under investigation by regulatory agencies. The report stated that industry insiders confirmed the authenticity of this news to the media. After the news came out, BeiGene's stock price fluctuated slightly in the three major capital markets of the Science and Technology Innovation Board, Hong Kong Stock Exchange, and US Stock Exchange in the afternoon, with the largest decline in the Science and Technology Innovation Board market falling by more than 3%.
A reporter from Huaxia Times called the Investor Relations Department of BeiGene, but when the call was answered, it showed that the contact person was not available and needed to leave a message. However, it later showed that the phone mailbox was full and unable to leave a message. As of the time of publication, no external contacts related to BeiGene have responded to the authenticity of the information regarding Yin Min.
The day before, the specific date for the 2024 medical insurance negotiations was announced. In recent years, Yin Min, as the Chief Business Officer of BeiGene Greater China, has appeared multiple times at the medical insurance negotiations. It is unknown whether this well-known pharmaceutical executive will arrive as scheduled this time. Huaxia Times will track the relevant news as soon as possible.
According to official information, Yin Min officially joined BeiGene in January 2022. Prior to this, she had held multiple positions at multinational pharmaceutical companies AstraZeneca and Eli Lilly. She worked at AstraZeneca for nearly 15 years, moving through multiple business departments.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Boeing executives attend accident investigation hearing 'one question, three unknowns'
- BlackRock executives harshly comment on 'non farm overhaul': interest rates too high, Fed should 'cut 50' in September!
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Affected by a large-scale strike, Boeing announced a freeze on recruitment and considers granting unpaid leave to employees, managers, and executives for non essential travel
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- Faraday Future: Jia Yueting and other executives purchase 10455 shares of Class A common stock in the company
- Pfizer CEO may meet with key executives of radical investor Starboard Value next week
-
10月23日、新東方は2025年度第1財季(2024年6月1日から8月31日)の財報を発表した。特筆すべきは、董宇輝が新東方を去った後、東方が選んだ初の季報だ。その中で、新東方はわざわざ東方が自社製品をオーディション ...
- 什么大师特
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
国内の革新的な薬企業がまた1発の深水爆弾を爆発させた。 10月25日、国内革新薬企業「一兄」百済神州大中華区の殷敏首席商務官が規制当局の調査を受けていることがメディアに暴露され、業界関係者がメディアにこの ...
- 刘moon
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
米国疾病管理・予防センターはこのほど、マクドナルドの「足三両」バーガーが同国西部の大腸菌疫病の発生と関係があり、49人が病気になり、1人が死亡したと明らかにした。マクドナルドは声明を発表し、大腸菌の疫病 ...
- SOHU
- 前天 09:34
- 支持
- 反对
- 回复
- 收藏
-
10月24日、テスラ米株式市場は12%以上上昇し、第3四半期の利益は予想を上回った。マースク氏は来年の自動車販売台数が20%-30%増加すると予測している。 ...
- 就放荡不羁就h
- 昨天 17:35
- 支持
- 反对
- 回复
- 收藏